Taiwan Liposome Company, Ltd is a pharmaceutical company specializing in developing technologies for sustained release, targeted delivery, and antibody-linked nanomedicines. It offers products and solutions for pain management, ophthalmology, oncology, infectious diseases, and systemic fungal infections. Operating in the pharmaceutical industry, the company targets the market for soft tissue sarcoma, rhabdomyosarcoma, non-small cell lung carcinoma, osteoarthritis pain, local anesthetic for post-surgical pain, and coronavirus disease 2019 (COVID-19). The company has developed a range of technologies including Ampholipad, ISPM19, BioSeizer, NanoX, and Polymeric Micelle. The number of employees and revenue are not disclosed.
Headquarters
11-1/F, No.3, Yuan Chu St., Taipei, Taiwan
Taipei City; Taipei City;
Contact Details: Purchase the Taiwan Liposome Company, Ltd. (台湾微脂体股份有限公司) report to view the information.
Website: http://www.tlcbio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service